Jaguar Health, Inc.

Jaguar was founded in San Francisco, California, as a Delaware corporation on June 6, 2013 (“inception”). The Company was a majority-owned subsidiary of Napo until the close of the Company’s initial public offering on May 18, 2015. The Company was formed to develop and commercialize first-in-class prescription and non-prescription products for companion animals. On July 31, 2017, Jaguar completed a merger with Napo pursuant to the Agreement and Plan of Merger dated March 31, 2017, by and among Jaguar, Napo, Napo Acquisition Corporation (“Merger Sub”), and Napo’s representative (the “Merger Agreement”). In accordance with the terms of the Merger Agreement, upon the completion of the merger, Merger Sub merged with and into Napo, with Napo surviving as the wholly owned subsidiary (the “Merger” or “Napo Merger”). Immediately following the Merger, Jaguar changed its name from “Jaguar Animal Health, Inc.” to “Jaguar Health, Inc.” Napo now operates as a wholly owned subsidiary of Jaguar focused on human health, including the ongoing development of crofelemer and commercialization of Mytesi.

Current securities

1. Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Unregistered Sales of Equity Securities · Other EventsSep 25, 2026
2. Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Other EventsSep 24, 2026
3. Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other EventsSep 21, 2026
4. PRE 14A filingSep 18, 2026
5. Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesSep 15, 2026